Cingulate to Present at LD Micro Investor Conference
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company, announced that Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022, at 10:00 a.m. PT. The event will take place at the Luxe Sunset Boulevard Hotel in Los Angeles, with live streaming available at this link. The company, utilizing its Precision Timed Release™ (PTR™) technology, focuses on developing next-generation pharmaceutical products for neurological disorders and other therapeutic areas.
- None.
- None.
KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022.
Conference and presentation details are as follows:
| Event: | LD Micro Main Event XV |
| Date: | Wednesday, October 26, 2022 |
| Presentation: | 10:00 a.m. Pacific Time |
| Live stream: | https://me22.mysequire.com/ |
| Location: | Luxe Sunset Boulevard Hotel, Los Angeles |
Management will host individual investor meetings. To arrange a meeting with Cingulate, please contact your conference representative. Investors may also contact Cingulate investor relations at mkreps@darrowir.com to arrange an in-person meeting.
About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of neurological disorders, Cingulate is identifying and evaluating additional therapeutic areas where PTR™ technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.
Investor Contact:
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301
Matt Kreps
Darrow Associates Investor Relations
214-597-8200
mkreps@darrowir.com
FAQ
What is Cingulate's participation in the LD Micro Main Event XV?
When is Cingulate's presentation at the LD Micro Main Event XV?
Where is the LD Micro Main Event XV conference being held?
How can I watch Cingulate's presentation live?
What technology does Cingulate use for its pharmaceutical products?
What are Cingulate's focuses in drug development?
